Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

NCT07301736 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

780

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: CHF5993 pMDI with HFA-152a
DRUG: CHF5993 pMDI with HFA-134a
DRUG: CHF718 pMDI with HFA-134a

Sponsor

Chiesi Farmaceutici S.p.A.